Table 5.
5-year OS | 5-year LPFS | |||||
---|---|---|---|---|---|---|
Adjusted factors | Hazard ratio (HR) | 95 % CI | p value | Hazard ratio (HR) | 95 % CI | p value |
IGRT vs Non-IGRT | 0.46 | 0.22–0.97 | 0.042 | 0.18 | 0.06–0.56 | 0.003 |
aXerostomia (Acute) | 0.92 | 0.45–1.88 | 0.813 | 1.32 | 0.53–3.33 | 0.554 |
Mucositis | 0.73 | 0.42–1.27 | 0.270 | 0.93 | 0.41–2.11 | 0.856 |
Dermatitis | 1.05 | 0.68–1.63 | 0.821 | 0.60 | 0.32–1.11 | 0.103 |
Body weight loss | 1.31 | 0.68–2.54 | 0.427 | 0.32 | 0.09–1.13 | 0.076 |
Dysphagia | 0.93 | 0.60–1.45 | 0.762 | 0.56 | 0.27–1.19 | 0.122 |
Fistula formation or superficial cases of skin dehiscence | 0.00 | 0.00–0.00 | 0.978 | 0.00 | 0.00–0.00 | 0.985 |
Anemia | 2.57 | 1.16–5.67 | 0.020 | 5.83 | 2.22–15.31 | 0.000 |
Leucopenia | 1.08 | 0.67–1.73 | 0.766 | 0.85 | 0.47–1.54 | 0.588 |
Thrombocytopenia | 0.62 | 0.29–1.33 | 0.220 | 0.59 | 0.23–1.38 | 0.206 |
Abbreviations: CI confidence Interval, IGRT image-guided radiotherapy, LPFS local progression-free survival rate, OS overall survival rate
aAcute xelostomia: Acute toxicity is defined as occurring < 90 days after beginning RT